<DOC>
	<DOCNO>NCT02100475</DOCNO>
	<brief_summary>This trial conduct globally . The aim trial compare sequential addition insulin aspart versus dose increase insulin degludec/liraglutide subject type 2 diabetes mellitus , previously treat insulin degludec/liraglutide metformin need intensification . This extension trial NN9068-3952 , NCT01952145 ( DUALâ„¢ V ) .</brief_summary>
	<brief_title>A Trial Comparing Sequential Addition Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide Subjects With Type 2 Diabetes Mellitus , Previously Treated With Insulin Degludec/Liraglutide Metformin Need Further Intensification</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Completion ( Visit 28 ) NN90683952 insulin degludec/liraglutide + metformin HbA1c ( glycosylated haemoglobin ) equal 7 percent Visit 27 NN90683952 trial Clinically significant disease major organ system Screening calcitonin equal 50 ng/L</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>